By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – T2 Biosystems, a molecular diagnostics startup based in Cambridge, Mass., today said that it has raised $15 million in a Series C financing.

The firm said that it will use the proceeds to accelerate development of its decentralized diagnostic platform, which it said eliminates extensive sample preparation and enables rapid molecular and immunodiagnostic testing on a single instrument.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

By analyzing tweets, Canadian researchers examine the public's view of gene patenting.

In Science this week: issues in reproducibility, circulating DNA predicts breast cancer relapse, and more.

Because of an autoimmune disorder, a man has been shedding live polioviruses for 28 years, according to an analysis appearing in PLOS Pathogens.

Being in a long-term collaboration can increase researchers' citation rates by 17 percent, a recent analysis says.

Sep
17
Sponsored by
Omicia

This online seminar will provide examples of how commercial and hospital-affiliated clinical labs are successfully developing and deploying high-throughput next-generation sequencing-based testing services for genetic diseases. 

Oct
15
Sponsored by
Parabase

This webinar will discuss the benefits of a rapid targeted next-generation sequencing (TNGS) panel, using dried blood spots, for second-tier newborn metabolic and hearing loss screening and its immediate utility for high-risk diagnostic testing in the neonatal intensive care unit. 

Oct
29
Sponsored by
Lucigen

This webinar will focus on a range of research and clinical applications enabled by improvements in mate pair technology for whole genome sequencing.